R&D Targeting COVID-19 and cancer with immunotherapy advancement... Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform.
News FDA backs Curium's Bexlutry as 1st 'radioligand equivalent' Curium's copycat version of Novartis GEP-NET therapy Lutathera, Bexlutry, is the first radioligand equivalent (RLE) to be approved by the FDA.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
